文拉法辛缓释剂与氯米帕明治疗门诊抑郁症患者的比较  

A comparative study of venlafaxin-extended-release and clomipramine in the treatment of outpatients with depression

作　　者：王鹤秋[1] 许本键[2] 金枝[2] 王素珍[1] 

机构地区：[1]浙江省立同德医院精神卫生研究院,311122 [2]杭州市公安局安康医院

出　　处：《上海精神医学》2004年第6期350-352,共3页Shanghai Archives of Psychiatry

摘　　要：目的　评价文拉法辛缓释剂(怡诺思)与氯米帕明(安拿芬尼)治疗门诊抑郁症的临床疗 效和安全性。方法　将80例抑郁症门诊患者依就诊顺序随机分为两组,分别给予文拉法辛缓释剂(n= 42)和氯米帕明(n=38)治疗,在2周内逐步增高剂量至150mg/d,在治疗前后用汉密尔顿抑郁量表 (HAMD)、汉密尔顿焦虑量表(HAMA)和副反应量表(TESS)评定疗效和不良反应。结果　文拉法辛 缓释剂与氯米帕明对抑郁症的治疗疗效相近,但前者起效更快,不良反应少于后者。结论　文拉法辛 缓释剂是安全、有效、依从性好、不良反应较少的新一代抗抑郁药。Objective: To compare clinical efficacy and safety between venlafaxine-XR and clomipramine in the treatment of depression. Methods: The 80 outpatients meeting with criteria of depression in CCMD-Ⅲ were received either venlafaxine or clomipramine for 6 weeks, at a dose titrated from 50 mg to a maximum of 150 mg/day during the first 10 days of treatment. Effects and adverse events were evaluated with HAMD、HAMA and TESS before and after the treatment. Results: It was found that efficacy of venlafaxine-XR was similar to clomipramine, however venlafaxine-XR took effect more quickly and its adverse events were less than clomipramine. Conclusion: Venlafaxine-XR is an effective and safe antidepressant.

关 键 词：文拉法辛缓释剂 氯米帕明 抑郁症 抗抑郁药 

分 类 号：R749.4[医药卫生—神经病学与精神病学]